Evidence map›Paper›PMID 40616779›Full record

ArticleACS infectious diseases2025

Design, Synthesis, and Antibacterial Evaluation of Rifampicin-Siderophore Conjugates.

Vladyslav Lysenko, Mei-Ling Gao, Fabienne A C Sterk, Paolo Innocenti, Cornelis J Slingerland, Nathaniel I Martin

Abstract read
In one paragraph

Article in ACS infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vladyslav LysenkoBiological Chemistry Group, Institute of Biology Leiden, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands.ORCID 0000-0001-9236-5821
Mei-Ling GaoBiological Chemistry Group, Institute of Biology Leiden, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands.
Fabienne A C SterkBiological Chemistry Group, Institute of Biology Leiden, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands.ORCID 0009-0006-8724-8528
Paolo InnocentiBiological Chemistry Group, Institute of Biology Leiden, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands.
Cornelis J SlingerlandBiological Chemistry Group, Institute of Biology Leiden, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands.ORCID 0000-0003-0027-7491
Nathaniel I MartinBiological Chemistry Group, Institute of Biology Leiden, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands.ORCID 0000-0001-8246-3006

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The growing concern over antibiotic resistance has sparked increased attention toward developing alternative antibiotic strategies. One promising approach, known as the "Trojan horse" strategy, involves the use of siderophores to hijack bacteria's iron transport systems as a way of delivering antibiotics inside the bacterial cell. This method is particularly promising in tackling Gram-negative bacteria, which have an outer membrane that many antibiotics cannot penetrate. One such antibiotic is rifampicin, a drug used to treat tuberculosis and infections caused by Gram-positive bacteria. Although rifampicin binds to a highly conserved bacterial RNA subunit, its activity is generally poor against Gram-negative bacteria due to their outer membrane. Aiming to expand rifampicin's efficacy, we here report the design and synthesis of several rifampicin-siderophore conjugates that exhibit enhanced activity against Gram-negative pathogens. Our findings indicate that the structural features of both the linker and catechol are crucial for the activity of conjugates with compound

Indexed as

Anti-Bacterial AgentsGram-Negative BacteriaRifampinSiderophoresDrug DesignMicrobial Sensitivity TestsAnti-Bacterial AgentsRifampinSiderophoresantibioticconjugateGram-negative bacteriaresistancerifampicinsiderophoreTrojan horse

Identifiers

PMID40616779
PMCPMC12340970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.